Understanding how a specific enzyme affects lung injury and respiratory distress
Official title: Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
Funded at Ohio State University · NIH-10857211 · Data updated 2026-11-12
This study is looking at how a special enzyme called TRMT1 affects lung health during serious conditions like acute lung injury and ARDS, with the hope of finding new ways to improve treatments for these illnesses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $517,676 |
| NIH project number | 5R01HL169586-02 |
| Project ID | NIH-10857211 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults who are experiencing or have a history of acute lung injury or ARDS.
✕Less likely to help
Patients with chronic lung diseases or those not experiencing acute respiratory issues may not benefit from this research.
What this research studies
This research investigates the role of a specific enzyme, TRMT1, and its impact on tRNA methylation in the context of acute lung injury and Acute Respiratory Distress Syndrome (ARDS). By examining how tRNA modifications respond to cellular stress and infection, the study aims to uncover new mechanisms that could lead to better treatments for ARDS. The research involves analyzing lung tissue samples and cellular responses to inflammatory stimuli to understand the enzyme's role in maintaining immune function and cell viability during critical illness.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel therapeutic strategies for treating ARDS, potentially reducing mortality and improving patient outcomes.
How similar studies have gone: While the specific focus on TRMT1 and tRNA methylation in ARDS is relatively novel, previous studies have shown that targeting cellular stress responses can lead to significant advancements in treating critical illnesses.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Londino, James David — Ohio State University
- Study coordinator: Londino, James David
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.